The startup has developed a monoclonal antibody platform that utilizes immunological expertise to induce immunotolerance in rat and guinea pig models, generating highly specific and high-affinity antibodies. This technology addresses the challenge of producing effective antibodies against poorly immunogenic targets, facilitating research and development for biopharmaceutical companies.
Funding
$310K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Generating high-quality monoclonal antibodies (mAbs) against small molecules, homologous antigens, and complex transmembrane proteins is challenging due to issues with immunogenicity and tolerance. Traditional antibody development methods often struggle to produce mAbs with the required specificity and affinity for these difficult targets.
Solution
SYnAbs addresses these challenges with a platform for generating custom rat-LOU monoclonal antibodies. The platform combines innovative antigen design, multi-species immunization, and strategic immunization techniques to break immune tolerance and target specific epitopes. SYnAbs leverages proprietary technologies, including the SYnDNA vector, SYnCell syngeneic cell lines, and an in-house adjuvant, to enhance immune responses. The company offers a comprehensive service from antigen synthesis to gram-scale manufacturing of high-specificity, high-affinity mAbs.
Target Audience
SYnAbs serves biotech, pharmaceutical, and in-vitro diagnostic companies requiring custom monoclonal antibodies for R&D, therapeutic, and diagnostic applications, particularly those targeting challenging antigens like haptens, transmembrane proteins, and homologous epitopes.
Features
- Proprietary rat-LOU species for immunization, known for strong immune responses to small molecules and homologous antigens
- SYnDNA vector, SYnCell syngeneic cell lines, and in-house adjuvant for innovative antigen design
- Multi-species immunization capabilities, including mice and alpacas, to maximize immune repertoire diversity
- Strategic immunization protocols to break immune tolerance and target specific epitopes
- Screening capabilities to isolate rare B cell populations with desired effector properties
- Animal-free cell culture for antibody manufacturing in shake-flasks, spinners, CELLines, and FiberCell systems
- Downstream processing steps, including affinity chromatography and endotoxin removal
- Quality control testing for aggregates, endotoxins, mycoplasma, bioburden, sterility, and kinetic features (Kd, Ka)
- Custom immunoassay development and optimization